首页 | 本学科首页   官方微博 | 高级检索  
     


Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes
Authors:Claire C. J. Dekkers MD  C. David Sjöström PhD  Peter J. Greasley PhD  Valerie Cain MS  David W. Boulton PhD  Hiddo J. L. Heerspink PhD
Affiliation:1. Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands;2. Late-stage Development, Cardiovascular, Renal and Metabolic, BioPharmaceuticals R&D, Astra Zeneca, Gothenburg, Sweden;3. Cardiovascular, Renal and Metabolism Translational Medicines Unit, Early Clinical Development, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden;4. Bogier Clinical and IT Solutions, Raleigh, North Carolina;5. Quantitative Clinical Pharmacology, IMED Biotech Unit, AstraZeneca, Gaithersburg, Maryland
Abstract:
Keywords:dapagliflozin  heart failure  SGLT2 inhibitor  type 2 diabetes
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号